EHA Library - The official digital education library of European Hematology Association (EHA)

PHASE I DOSE ESCALATION OF LAVA-051, A NOVEL BISPECIFIC GAMMA-DELTA T-CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES
Author(s): ,
Annemiek Broijl
Affiliations:
Department of Hematology,Erasmus MC Cancer Institute,Rotterdam,Pays-bas;Department of Hematology,Erasmus MC Cancer Institute,Rotterdam,Niederlande;Department of Hematology,Erasmus MC Cancer Institute,Rotterdam,Paesi Bassi;Department of Hematology,Erasmus MC Cancer Institute,Rotterdam,Netherland;Department of Hematology,Erasmus MC Cancer Institute,Rotterdam,Países Bajos;Department of Hematology,Era
,
Niels van de Donk
Affiliations:
Department of Hematology,Cancer Care Amsterdam, Amsterdam UMC,Amsterdam,Pays-bas;Department of Hematology,Cancer Care Amsterdam, Amsterdam UMC,Amsterdam,Niederlande;Department of Hematology,Cancer Care Amsterdam, Amsterdam UMC,Amsterdam,Paesi Bassi;Department of Hematology,Cancer Care Amsterdam, Amsterdam UMC,Amsterdam,Netherland;Department of Hematology,Cancer Care Amsterdam, Amsterdam UMC,Amster
,
Francesc Bosch
Affiliations:
Department of Hematology,Hospital Vall d'Hebron,Barcelona,Espagne;Department of Hematology,Hospital Vall d'Hebron,Barcelona,Spanien;Department of Hematology,Hospital Vall d'Hebron,Barcelona,Spagna;Department of Hematology,Hospital Vall d'Hebron,Barcelona,Spain;Department of Hematology,Hospital Vall d'Hebron,Barcelona,España;Department of Hematology,Hospital Vall d'Hebron,Barcelona,Spanje;Departmen
,
Maria V. Mateos
Affiliations:
Institute of Cancer Molecular and Cellular Biology,University Hospital of Salamanca,Salamanca,Espagne;Institute of Cancer Molecular and Cellular Biology,University Hospital of Salamanca,Salamanca,Spanien;Institute of Cancer Molecular and Cellular Biology,University Hospital of Salamanca,Salamanca,Spagna;Institute of Cancer Molecular and Cellular Biology,University Hospital of Salamanca,Salamanca,S
,
Paula Rodriguez-Otero
Affiliations:
Department of Hematology,Clínica Universidad De Navarra,Pamplona,Espagne;Department of Hematology,Clínica Universidad De Navarra,Pamplona,Spanien;Department of Hematology,Clínica Universidad De Navarra,Pamplona,Spagna;Department of Hematology,Clínica Universidad De Navarra,Pamplona,Spain;Department of Hematology,Clínica Universidad De Navarra,Pamplona,España;Department of Hematology,Clínica Univer
,
Alessandra Tucci
Affiliations:
Department of Hematology,ASST Spedali Civili di Brescia,Brescia,Italie;Department of Hematology,ASST Spedali Civili di Brescia,Brescia,Italien;Department of Hematology,ASST Spedali Civili di Brescia,Brescia,Italia;Department of Hematology,ASST Spedali Civili di Brescia,Brescia,Italy;Department of Hematology,ASST Spedali Civili di Brescia,Brescia,Italia;Department of Hematology,ASST Spedali Civili
,
Paolo Ghia
Affiliations:
Division of Experimental Oncology,Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele,Milano,Italie;Division of Experimental Oncology,Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele,Milano,Italien;Division of Experimental Oncology,Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele,Milano,Italia;Division of Experimental Oncology,Università Vita-S
,
Anton Adang
Affiliations:
LAVA Therapeutics N.V.,Utrecht,Pays-bas;LAVA Therapeutics N.V.,Utrecht,Niederlande;LAVA Therapeutics N.V.,Utrecht,Paesi Bassi;LAVA Therapeutics N.V.,Utrecht,Netherland;LAVA Therapeutics N.V.,Utrecht,Países Bajos;LAVA Therapeutics N.V.,Utrecht,Nederland;LAVA Therapeutics N.V.,Utrecht,Holanda;LAVA Therapeutics N.V.,Utrecht,Нидерланды;LAVA Therapeutics N.V.,Utrecht,Nederländerna
,
Paul Parren
Affiliations:
LAVA Therapeutics N.V.,Utrecht,Pays-bas;LAVA Therapeutics N.V.,Utrecht,Niederlande;LAVA Therapeutics N.V.,Utrecht,Paesi Bassi;LAVA Therapeutics N.V.,Utrecht,Netherland;LAVA Therapeutics N.V.,Utrecht,Países Bajos;LAVA Therapeutics N.V.,Utrecht,Nederland;LAVA Therapeutics N.V.,Utrecht,Holanda;LAVA Therapeutics N.V.,Utrecht,Нидерланды;LAVA Therapeutics N.V.,Utrecht,Nederländerna
,
Ilse Tuinhof
Affiliations:
LAVA Therapeutics N.V.,Utrecht,Pays-bas;LAVA Therapeutics N.V.,Utrecht,Niederlande;LAVA Therapeutics N.V.,Utrecht,Paesi Bassi;LAVA Therapeutics N.V.,Utrecht,Netherland;LAVA Therapeutics N.V.,Utrecht,Países Bajos;LAVA Therapeutics N.V.,Utrecht,Nederland;LAVA Therapeutics N.V.,Utrecht,Holanda;LAVA Therapeutics N.V.,Utrecht,Нидерланды;LAVA Therapeutics N.V.,Utrecht,Nederländerna
,
Sanjana Umarale
Affiliations:
LAVA Therapeutics N.V.,Utrecht,Pays-bas;LAVA Therapeutics N.V.,Utrecht,Niederlande;LAVA Therapeutics N.V.,Utrecht,Paesi Bassi;LAVA Therapeutics N.V.,Utrecht,Netherland;LAVA Therapeutics N.V.,Utrecht,Países Bajos;LAVA Therapeutics N.V.,Utrecht,Nederland;LAVA Therapeutics N.V.,Utrecht,Holanda;LAVA Therapeutics N.V.,Utrecht,Нидерланды;LAVA Therapeutics N.V.,Utrecht,Nederländerna
,
Benjamin Winograd
Affiliations:
LAVA Therapeutics N.V.,Utrecht,Pays-bas;LAVA Therapeutics N.V.,Utrecht,Niederlande;LAVA Therapeutics N.V.,Utrecht,Paesi Bassi;LAVA Therapeutics N.V.,Utrecht,Netherland;LAVA Therapeutics N.V.,Utrecht,Países Bajos;LAVA Therapeutics N.V.,Utrecht,Nederland;LAVA Therapeutics N.V.,Utrecht,Holanda;LAVA Therapeutics N.V.,Utrecht,Нидерланды;LAVA Therapeutics N.V.,Utrecht,Nederländerna
,
Hans van der Vliet
Affiliations:
LAVA Therapeutics N.V.,Utrecht,Pays-bas;LAVA Therapeutics N.V.,Utrecht,Niederlande;LAVA Therapeutics N.V.,Utrecht,Paesi Bassi;LAVA Therapeutics N.V.,Utrecht,Netherland;LAVA Therapeutics N.V.,Utrecht,Países Bajos;LAVA Therapeutics N.V.,Utrecht,Nederland;LAVA Therapeutics N.V.,Utrecht,Holanda;LAVA Therapeutics N.V.,Utrecht,Нидерланды;LAVA Therapeutics N.V.,Utrecht,Nederländerna
Arnon Kater
Affiliations:
Department of Hematology,Cancer Care Amsterdam, Amsterdam UMC,Amsterdam,Pays-bas;Department of Hematology,Cancer Care Amsterdam, Amsterdam UMC,Amsterdam,Niederlande;Department of Hematology,Cancer Care Amsterdam, Amsterdam UMC,Amsterdam,Paesi Bassi;Department of Hematology,Cancer Care Amsterdam, Amsterdam UMC,Amsterdam,Netherland;Department of Hematology,Cancer Care Amsterdam, Amsterdam UMC,Amster
(Abstract release date: 05/12/22) EHA Library. Broijl A. 06/10/22; 358320; P1463
Annemiek Broijl
Annemiek Broijl
Contributions
Abstract
Presentation during EHA2022: All (e)Poster presentations will be made available as of Friday, June 10, 2022 (09:00 CEST) and will be accessible for on-demand viewing until Monday, August 15, 2022 on the Congress platform.

Abstract: P1463

Type: Poster presentation

Session title: Gene therapy, cellular immunotherapy and vaccination - Clinical

Background
LAVA-051 is a 27kD humanized bispecific single domain antibody (VHH) that directly engages CD1d and the Vδ2-TCR chain of Vγ9Vδ2-T cells and additionally stabilizes the interaction between CD1d and type 1 NKT cells (Nature Cancer 2020;1:1054-1065) to mediate potent killing of CD1d-expressing tumor cells. By engaging innate-like T cell subsets with inherent antitumor activity, namely Vγ9Vδ2-T and type 1 NKT cells, LAVA-051 has the potential to combine high therapeutic efficacy with limited off-tumor toxicity. CD1d is expressed by tumor cells in the majority of patients with CLL (chronic lymphocytic leukemia) and MM (multiple myeloma), while expression in AML (acute myeloid leukemia) is most pronounced on (myelo)monocytic subtypes. Tolerability studies in non-human primates with cross-reactive surrogate bispecific γδ-T cell engagers showed a good safety profile without signs of CRS (cytokine release syndrome). 

Aims
To provide initial dose escalation findings from a First In Human Study of LAVA-051 in relapsed/refractory hematologic malignancies.

Methods
This is an open label, accelerated titration design, phase 1/2a study in patients with relapsed/ refractory CLL, MM, and AML (NCT04887259). The phase 1 study starts with single-patient cohorts for the first 3 dose levels followed by a 3+3 design. The primary objectives of the study are to investigate the safety and tolerability of LAVA-051 and to determine its recommended Phase 2a dose (RP2D). Secondary objectives of the study include evaluation of PK, PD, immunogenicity, and preliminary antitumor activity. The (flat) starting dose was determined to be 0.45 µg. LAVA-051 is administered by IV infusion over 2 hours twice a week. Informed consent has been obtained from all participating patients.

Results
As of Feb 14, 2022, a dose level of 45 µg has been reached with no reports of CRS (ASTCT grading) or dose limiting toxicities (DLTs). Six patients in total have been treated with LAVA-051; 4 patients (2 MM, 2 CLL) were evaluable for DLTs during cycle 1 at dose levels 0.45 µg, 3 µg, 15 µg and 45 µg. Treatment emergent AEs (TEAEs) (CTCAEv5.0) were predominantly of grade 1 and 2 severity (e.g. fever, chills, and headache) . One patient (45 µg) reported a grade 2 infusion related reaction (IRR) that lasted less than 12 hours following the first administration only. Frequency and severity of TEAEs did not increase with escalating doses and all TEAEs were reversible. One patient with CLL developed symptoms consistent with a tumor flare reaction during cycle 1, and continues on cycle 5 of treatment with stable disease at 15 µg. PK data indicate increasing drug exposure in correlation with increasing doses of LAVA-051, and PD data indicate a dose-dependent increase in LAVA-051 receptor occupancy of the Vγ9Vδ2-T cell receptor. Importantly, no consistent or significant changes in measured cytokines have been observed. Updated results will be presented at the congress.

Conclusion
LAVA-051 has been well tolerated early in dose escalation with on-mechanism pharmacodynamics consistent with Vγ9Vδ2-T cell engagement.

Keyword(s): Bispecific, Phase I

Presentation during EHA2022: All (e)Poster presentations will be made available as of Friday, June 10, 2022 (09:00 CEST) and will be accessible for on-demand viewing until Monday, August 15, 2022 on the Congress platform.

Abstract: P1463

Type: Poster presentation

Session title: Gene therapy, cellular immunotherapy and vaccination - Clinical

Background
LAVA-051 is a 27kD humanized bispecific single domain antibody (VHH) that directly engages CD1d and the Vδ2-TCR chain of Vγ9Vδ2-T cells and additionally stabilizes the interaction between CD1d and type 1 NKT cells (Nature Cancer 2020;1:1054-1065) to mediate potent killing of CD1d-expressing tumor cells. By engaging innate-like T cell subsets with inherent antitumor activity, namely Vγ9Vδ2-T and type 1 NKT cells, LAVA-051 has the potential to combine high therapeutic efficacy with limited off-tumor toxicity. CD1d is expressed by tumor cells in the majority of patients with CLL (chronic lymphocytic leukemia) and MM (multiple myeloma), while expression in AML (acute myeloid leukemia) is most pronounced on (myelo)monocytic subtypes. Tolerability studies in non-human primates with cross-reactive surrogate bispecific γδ-T cell engagers showed a good safety profile without signs of CRS (cytokine release syndrome). 

Aims
To provide initial dose escalation findings from a First In Human Study of LAVA-051 in relapsed/refractory hematologic malignancies.

Methods
This is an open label, accelerated titration design, phase 1/2a study in patients with relapsed/ refractory CLL, MM, and AML (NCT04887259). The phase 1 study starts with single-patient cohorts for the first 3 dose levels followed by a 3+3 design. The primary objectives of the study are to investigate the safety and tolerability of LAVA-051 and to determine its recommended Phase 2a dose (RP2D). Secondary objectives of the study include evaluation of PK, PD, immunogenicity, and preliminary antitumor activity. The (flat) starting dose was determined to be 0.45 µg. LAVA-051 is administered by IV infusion over 2 hours twice a week. Informed consent has been obtained from all participating patients.

Results
As of Feb 14, 2022, a dose level of 45 µg has been reached with no reports of CRS (ASTCT grading) or dose limiting toxicities (DLTs). Six patients in total have been treated with LAVA-051; 4 patients (2 MM, 2 CLL) were evaluable for DLTs during cycle 1 at dose levels 0.45 µg, 3 µg, 15 µg and 45 µg. Treatment emergent AEs (TEAEs) (CTCAEv5.0) were predominantly of grade 1 and 2 severity (e.g. fever, chills, and headache) . One patient (45 µg) reported a grade 2 infusion related reaction (IRR) that lasted less than 12 hours following the first administration only. Frequency and severity of TEAEs did not increase with escalating doses and all TEAEs were reversible. One patient with CLL developed symptoms consistent with a tumor flare reaction during cycle 1, and continues on cycle 5 of treatment with stable disease at 15 µg. PK data indicate increasing drug exposure in correlation with increasing doses of LAVA-051, and PD data indicate a dose-dependent increase in LAVA-051 receptor occupancy of the Vγ9Vδ2-T cell receptor. Importantly, no consistent or significant changes in measured cytokines have been observed. Updated results will be presented at the congress.

Conclusion
LAVA-051 has been well tolerated early in dose escalation with on-mechanism pharmacodynamics consistent with Vγ9Vδ2-T cell engagement.

Keyword(s): Bispecific, Phase I

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies